Short answer
ZEVRA THERAPEUTICS, INC. (ZVRA) filed an 8-K current report with the SEC on March 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 5.02 (Departure/Election of Directors or Officers). Q4 2025 earnings release issued March 9, 2026: full financial results and corporate updates in Exhibit 99.1.
ZEVRA THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q4 2025 earnings release issued March 9, 2026: full financial results and corporate updates in Exhibit 99.1
- Conference call/webcast scheduled March 9, 2026 at 4:30 p.m. ET to discuss results
- Press release furnished (not filed) under SEC rules: limits legal liability but does not affect informational value
Item 5.02 · Departure/Election of Directors or Officers
- Justin Renz appointed CFO effective March 9, 2026; seasoned biopharma CFO with prior roles at Ardelyx, Correvio, and Karyopharm
- Base salary $520,000 with 45% annual bonus target (~$234,000 target bonus)
- Equity grant of 300,000 stock options at fair market value, vesting equally over 4 years (25%/year)
- Termination without cause triggers 12-month base salary continuation plus prorated target bonus and accelerated vesting
- Timothy Sangiovanni steps down as principal financial officer March 10, 2026, retaining SVP Finance/Controller role
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ZEVRA THERAPEUTICS, INC. 8-K filings
Get the next ZVRA 8-K as it lands
Follow ZVRA for push alerts, or ask the research agent what this filing means.